Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3

被引：0
|
作者：
Park, K. [1 ]
Tan, D. [2 ]
Ahn, M. -J. [3 ]
Yu, C. -J. [4 ]
Tsai, C. -M. [5 ]
Hida, T. [6 ]
Nishio, M. [7 ]
Branle, F. [8 ]
Emeremni, C. [9 ]
Mok, T. [10 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Med Oncol, Singapore, Singapore
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] Natl Taiwan Univ, Dept Internal Med, Taipei 10764, Taiwan
[5] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[6] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[7] Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo, Japan
[8] Novartis Pharma AG, Oncol Clin Dev, Basel, Switzerland
[9] Novartis Pharma AG, Biometr & Data Management, E Hanover, NJ USA
[10] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419O
引用
收藏
页码：126 / 127
页数：2
相关论文
共 50 条
  • [21] Cystic brain metastases in ALK-rearranged non-small cell lung cancer
    Marta, Guilherme Nader
    da Cunha Colombo Bonadio, Renata Rodrigues
    Martins, Renata Eiras
    Zuppani, Henrique Bortot
    de Castro Junior, Gilberto
    ECANCERMEDICALSCIENCE, 2018, 12
  • [22] ALK-rearranged Non-Small Cell Lung Cancer Cystic Brain Metastases
    Lakhani, Dhairya A.
    Deng, Francis
    RADIOLOGY, 2024, 313 (01)
  • [23] ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with crizotinib
    Zhang, L.
    Shi, Y.
    Tan, D. S. W.
    Hu, B.
    Xiaoqing, L.
    Cheng, Y.
    Zhou, J.
    An, T.
    Lu, Y.
    Zhu, B.
    Bai, C.
    Jappe, A.
    Passos, V. Q.
    Lau, Y. Y.
    Wang, Q.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK plus ) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
    De Castro, Gilberto, Jr.
    Tan, Daniel Shao-Weng
    Crino, Lucio
    Wu, Yi Long
    Paz-Ares, Luis
    Wolf, Juergen
    Geater, Sarayut
    Orlov, Sergey
    Cortinovis, Diego
    Yu, Chong-Jen
    Hochmair, Maximilian
    Cortot, Alexis
    Tsai, Chun-Ming
    Moro-Sibilot, Denis
    Campelo, Rosario Garcia
    Branle, Fabrice
    Sen, Paramita
    Mcculloch, Tracey
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S7 - S7
  • [25] ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
    Chow, Laura Q. M.
    Barlesi, Fabrice
    Bertino, Erin M.
    van den Bent, Martin J.
    Wakelee, Heather A.
    Wen, Patrick Y.
    Chiu, Chao-Hua
    Orlov, Sergey
    Chiari, Rita
    Majem, Margarita
    McKeage, Mark
    Yu, Chong-Jen
    Garrido, Pilar
    Hurtado, Felipe K.
    Arratia, Pilar Cazorla
    Song, Yuanbo
    Branle, Fabrice
    Shi, Michael
    Kim, Dong-Wan
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2506 - 2516
  • [26] Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
    Tan, Daniel S. W.
    Geater, Sarayut
    Yu, Chong-Jen
    Tsai, Chun -Ming
    Hsia, Te-Chun
    Chen, Jun
    Lin, Meng-Chih
    Lu, You
    Sriuranpong, Virote
    Yang, Cheng-Ta
    Sen, Paramita
    Branle, Fabrice
    Shi, Michael
    Wu, Yi-Long
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (03):
  • [27] First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK1) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
    Tan, D. S.
    Geater, S.
    Yu, C. J.
    Tsai, C. M.
    Hsia, T. C.
    Zhou, J.
    Chen, J.
    Lin, M. C.
    Yu, P.
    He, J.
    Li, W.
    Lu, Y.
    Sriuranpong, V.
    Yang, C. T.
    Sen, P.
    Branle, F.
    Shi, M.
    Wu, Y. L.
    ANNALS OF ONCOLOGY, 2019, 30 : 599 - +
  • [28] Safety and efficacy profile of Ceritinib (LDK378) in ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC)
    Chaigneau, Aurelie
    Durand, Lea
    Lallart, Audrey
    Laghouati, Salim
    Demirdjian, Sylvie
    Pinel, Sylvine
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (01) : 211 - 211
  • [29] Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure
    Oya, Yuko
    Yoshida, Tatsuya
    Kuroda, Hiroaki
    Shimizu, Junichi
    Horio, Yoshitsugu
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    ANTICANCER RESEARCH, 2017, 37 (11) : 6477 - 6480
  • [30] Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
    Crino, Lucio
    Ahn, Myung-Ju
    De Marinis, Filippo
    Groen, Harry J. M.
    Wakelee, Heather
    Hida, Toyoaki
    Mok, Tony
    Spigel, David
    Felip, Enriqueta
    Nishio, Makoto
    Scagliotti, Giorgio
    Branle, Fabrice
    Emeremni, Chetachi
    Quadrigli, Massimiliano
    Zhang, Jie
    Shaw, Alice T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) : 2866 - +
12345